Sinovac Biotech Ltd.
- SVA ยท Nasdaq
- Pharmaceutical Preparations
- Beijing, China
- 2,602 employees
- CIK 0001084201
Updated from SEC filings through
Top things to know
Executives
- Yin Weidong Chief Executive Officer Form 3, March 18, 2026
- Nan Wang Chief Financial Officer Form 3, March 18, 2026
- Guang (Helen) Yang Chief Business Officer Form 3, March 18, 2026
- Qiang (Nmn) Gao Chief Operation Officer Form 3, March 18, 2026
- Jing (Nmn) Li VP, Quality and Production Form 3, March 18, 2026
Sinovac Biotech Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Beijing, China. It trades as SVA on Nasdaq. Revenue was $386M in the fiscal year ending December 31, 2025, +6.8% from the year before. It reported about 2,602 employees. Yin Weidong is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $386M 20-F, 2026-06-05 | $361M 20-F, 2026-06-05 | $470M 20-F, 2026-06-05 | $1.5B 20-F, 2026-04-30 | $19.4B 20-F, 2026-04-30 |
| Operating income | -$490M 20-F, 2026-06-05 | -$506M 20-F, 2026-06-05 | -$714M 20-F, 2026-06-05 | -$509M 20-F, 2026-04-30 | $17.6B 20-F, 2026-04-30 |
| SG&A | $333M 20-F, 2026-06-05 | $421M 20-F, 2026-06-05 | $598M 20-F, 2026-06-05 | $836M 20-F, 2026-04-30 | $602M 20-F, 2026-04-30 |
| Net income | -$199M 20-F, 2026-06-05 | $40.7M 20-F, 2026-06-05 | -$13.5M 20-F, 2026-04-30 | $14.5M 20-F, 2026-04-30 | $8.1B 20-F, 2026-04-30 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Yin Weidong Chairman, President & CEO at SINOVAC BIOTECH LTD. | Chief Executive Officer | Form 3, March 18, 2026 |
| Nan Wang | Chief Financial Officer | Form 3, March 18, 2026 |
| Guang (Helen) Yang | Chief Business Officer | Form 3, March 18, 2026 |
| Qiang (Nmn) Gao | Chief Operation Officer | Form 3, March 18, 2026 |
| Jing (Nmn) Li | VP, Quality and Production | Form 3, March 18, 2026 |
What Sinovac Biotech Ltd does
We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs. We have developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus..
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 71.9 million (as of December 31, 2025) | 20-F, June 5, 2026 |
|---|---|---|
| Public float | $0 (as of December 31, 2011) | 20-F, April 12, 2012 |
| Reportable segments | 1 (period ending December 31, 2025) | 20-F, June 5, 2026 |
| Auditor | Zhonghua Certified Public Accountants LLP (Shanghai, China) | Latest 10-K |
Recent 8-K events
- 8-K filed 2000-10-26
- Item 4 Item 4
Frequently asked questions about Sinovac Biotech Ltd
- What does Sinovac Biotech Ltd do?
- In its own words, from Item 1 of its 10-K: "We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs. We have developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus.."
- What is Sinovac Biotech Ltd's revenue?
- $386M for the fiscal year ending December 31, 2025, from its 20-F filed June 5, 2026.
- Is Sinovac Biotech Ltd profitable?
- Sinovac Biotech Ltd reported net income of -$199M for the fiscal year ending December 31, 2025.
- How many employees does Sinovac Biotech Ltd have?
- About 2,602 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Sinovac Biotech Ltd?
- Yin Weidong, Chief Executive Officer, as named in a 3 filed March 18, 2026.
- Who is the CFO of Sinovac Biotech Ltd?
- Nan Wang, Chief Financial Officer, as named in a 3 filed March 18, 2026.
- Where is Sinovac Biotech Ltd headquartered?
- Beijing, China.
- What is Sinovac Biotech Ltd's stock ticker?
- SVA on Nasdaq.
- What industry is Sinovac Biotech Ltd in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Sinovac Biotech Ltd's website?
- sinovac.com. Investor relations: https://www.sinovac.com/en-us/Investors.
- Is Sinovac Biotech Ltd a public company?
- Yes. Sinovac Biotech Ltd files with the SEC under CIK 0001084201 and trades as SVA.
- Who audits Sinovac Biotech Ltd?
- Zhonghua Certified Public Accountants LLP, Shanghai, China, as named in its latest annual report (10-K).
- How many shares of Sinovac Biotech Ltd are outstanding?
- 71.9 million shares as of December 31, 2025, from its 20-F filed June 5, 2026.
- What is Sinovac Biotech Ltd's public float?
- $0 as of December 31, 2011, as reported on the cover of its 20-F filed April 12, 2012.
- How many business segments does Sinovac Biotech Ltd report?
- 1 reportable segment for the period ending December 31, 2025, from its 20-F filed June 5, 2026.